Tracking every rollback, reversal, and overreach — and the path back to the America we know.
Executive Order 14293 signed on May 5, 2025, removes regulatory barriers to increase domestic production of critical medicines in the United States. The order streamlines FDA approval processes and reduces compliance requirements for pharmaceutical manufacturers. This aims to reduce American dependence on foreign drug sources and lower medication costs for consumers.
The Trump administration ousted FDA acting drug chief Dr. Tracy Beth Høeg, acting vaccines chief Katherine Szarama, and chief of staff Jim Traficant in a major leadership shake-up. The agency now lacks a permanent commissioner and stable leadership during critical drug approval and vaccine oversight functions. The departure of experienced regulators weakens FDA capacity to evaluate drug safety and vaccine efficacy during a period of potential regulatory rollback.
The Trump administration's budget law mandates work requirements for Medicaid beneficiaries, with Nebraska implementing the policy on May 1 and most states required to follow by January. The requirement forces many low-income Americans to prove employment to maintain health coverage, directly affecting millions of vulnerable populations who may struggle to meet work documentation standards.
President Trump signed Executive Order 14273 on April 15, 2025, implementing measures aimed at lowering prescription drug prices for American consumers. The order directs federal agencies to reduce pharmaceutical costs through regulatory reform and market mechanisms. This action is intended to decrease out-of-pocket medication expenses for Medicare, Medicaid, and privately insured Americans.
The Trump administration prohibited federal funding for fentanyl test strips while simultaneously supporting naloxone access, creating contradictory overdose prevention policies. Experts say the restriction on test strips—which help people identify dangerous drugs and avoid overdoses—strains health resources and increases overdose risk. The conflicting approaches undermine harm reduction efforts nationwide.
On February 18, 2025, President Trump signed Executive Order 14216 directing federal agencies to expand access to in vitro fertilization (IVF) services. The order instructs relevant agencies to remove regulatory barriers and increase IVF availability through federal health programs and supported facilities. The confirmed direct impact includes expanded IVF coverage eligibility and reduced administrative obstacles for Americans seeking fertility treatment through federally-supported healthcare.
The Trump administration's Department of Justice fired prosecutors accused of coordinating with abortion-rights advocacy groups during the Biden administration. Hours later, DOJ officials met with anti-abortion advocates. This action impacts federal prosecutors and signals the administration's shift toward stricter enforcement against abortion-related advocacy.
Defense Secretary Pete Hegseth announced the Pentagon is ending mandatory flu vaccination requirements for active duty service members, citing medical autonomy and religious freedom. The policy change removes a long-standing health requirement for all U.S. military personnel, potentially affecting disease prevention protocols across the armed forces.
The Trump administration reversed its policy allowing federal funds for purchasing and distributing fentanyl detection strips used to test street drugs for contaminants. The Substance Abuse and Mental Health Services Administration issued guidance ending the practice as part of the administration's opposition to harm reduction initiatives. This change eliminates access to potentially life-saving drug testing resources for vulnerable populations.
Acting Attorney General Todd Blanche signed an order reclassifying state-licensed medical marijuana to a less-dangerous drug category under federal law. The change impacts federal regulation of marijuana in dozens of states that permit medical use, though it does not fully legalize marijuana federally. This significantly alters how the drug is regulated and enforced at the federal level.